April 29th 2021
Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.
April 21st 2021
Although the malignancy has an encouraging survival rate, it is necessary to be aware of the complexity of nasopharyngeal cancer.
April 19th 2021
Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.
April 15th 2021
Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.
April 14th 2021
Innovative robotic technology helps to improve surgical outcomes and safety for patients while advancing the field of ENT surgery.
April 10th 2021
Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.
April 8th 2021
The FDA has granted a fast track designation to the soluble LAG-3 protein eftilagimod alpha for use in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
April 7th 2021
The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
March 30th 2021
Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.